(DNLI) Denali Therapeutics - Ratings and Ratios
Therapeutic, Neurodegenerative, Lysosomal, Inhibitors, Therapies
DNLI EPS (Earnings per Share)
DNLI Revenue
Description: DNLI Denali Therapeutics
Denali Therapeutics Inc. is a biopharmaceutical company that focuses on developing innovative treatments for neurodegenerative and lysosomal storage diseases, with a robust pipeline of programs targeting various conditions, including Parkinsons disease, amyotrophic lateral sclerosis, and lysosomal storage disorders such as Hunter Syndrome and Pompe disease.
The companys diverse portfolio includes several promising candidates, such as Eclitasertib, a RIPK1 inhibitor for peripheral inflammatory diseases, and DNL343, an eIF2B activator for amyotrophic lateral sclerosis. Additionally, Denali Therapeutics is developing Enzyme Transport Vehicle (ETV) and Oligonucleotide Transport Vehicle (OTV) programs, which aim to improve the delivery of therapeutic molecules across the blood-brain barrier, potentially revolutionizing the treatment of neurodegenerative diseases.
With a strong research and development focus, Denali Therapeutics has established partnerships with major pharmaceutical companies, such as Biogen and Takeda, to advance its pipeline and bring new treatments to market. The companys headquarters is located in South San Francisco, California, a hub for biotech innovation.
Analyzing the
Our forecast is based on a combination of technical and fundamental analysis. The current price is above the 20-day and 50-day SMAs, indicating a short-term uptrend. However, the 200-day SMA is significantly higher, suggesting a longer-term downtrend. The high ATR indicates significant volatility, which may lead to a correction. From a fundamental perspective, the companys negative P/E ratio and RoE indicate that it is still in the development stage and has not yet generated significant revenue. However, the market capitalization suggests that investors are optimistic about the companys potential. As the company advances its pipeline and achieves clinical milestones, we expect the stock price to rebound and potentially reach $20.00 in the long term.
Additional Sources for DNLI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
DNLI Stock Overview
Market Cap in USD | 2,165m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2017-12-08 |
DNLI Stock Ratings
Growth Rating | -60.9 |
Fundamental | -60.0 |
Dividend Rating | 0.0 |
Rel. Strength | -29.2 |
Analysts | 4.79 of 5 |
Fair Price Momentum | 10.81 USD |
Fair Price DCF | - |
DNLI Dividends
Currently no dividends paidDNLI Growth Ratios
Growth Correlation 3m | 15.6% |
Growth Correlation 12m | -81.1% |
Growth Correlation 5y | -83.7% |
CAGR 5y | -10.15% |
CAGR/Max DD 5y | -0.12 |
Sharpe Ratio 12m | 0.40 |
Alpha | -61.37 |
Beta | 2.165 |
Volatility | 63.38% |
Current Volume | 1691.8k |
Average Volume 20d | 1485.1k |
Stop Loss | 13.7 (-5.6%) |
As of July 12, 2025, the stock is trading at USD 14.52 with a total of 1,691,793 shares traded.
Over the past week, the price has changed by +1.89%, over one month by -4.41%, over three months by +14.33% and over the past year by -37.12%.
No, based on ValueRay´s Fundamental Analyses, Denali Therapeutics (NASDAQ:DNLI) is currently (July 2025) a stock to sell. It has a ValueRay Fundamental Rating of -59.96 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DNLI is around 10.81 USD . This means that DNLI is currently overvalued and has a potential downside of -25.55%.
Denali Therapeutics has received a consensus analysts rating of 4.79. Therefore, it is recommended to buy DNLI.
- Strong Buy: 15
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, DNLI Denali Therapeutics will be worth about 13 in July 2026. The stock is currently trading at 14.52. This means that the stock has a potential downside of -10.67%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 32.2 | 121.7% |
Analysts Target Price | 32.2 | 121.7% |
ValueRay Target Price | 13 | -10.7% |